scholarly journals Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis

2017 ◽  
Vol Volume 10 ◽  
pp. 3625-3634 ◽  
Author(s):  
Cong Dai ◽  
Meng Wang ◽  
Jun Lu ◽  
Zhiming Dai ◽  
Shuai Lin ◽  
...  
Keyword(s):  
Digestive System ◽  
Meta Analysis ◽  
Predictive Values ◽  
Digestive System Cancer

scholarly journals Pretreatment Lymphocyte Monocyte Ratio Predicts Long-Term Outcomes in Patients with Digestive System Tumor: A Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Jingwen Zhang ◽  
Lishan Chen ◽  
Rui Zhou ◽  
Huiying Sun ◽  
Yulin Liao ◽  
...  
Keyword(s):  
Digestive System ◽  
Meta Analysis ◽  
Disease Recurrence ◽  
Sensitivity Analyses ◽  
Prognostic Impact ◽  
Cancer Specific Survival ◽  
Digestive System Cancer ◽  
Hazard Ratios ◽  
System Tumor

Purpose.The prognostic value of pretreatment lymphocyte monocyte ratio (LMR) in digestive system cancer patients remains controversial. The aim of this study was to quantify the prognostic impact of this biomarker and assess its consistency in digestive system tumors.Methods.We searched “PubMed,” “Embase,” and “CBM” for published eligible studies before June 2016 and conducted a meta-analysis to estimate the pooled hazard ratios (HRs) for disease recurrence and mortality focusing on LMR. Subgroup analyses, meta-regression, and sensitivity analyses were also performed.Results.A total of 22 cohort studies enrolling 12829 patients with digestive system cancer were included. The summary results showed that lower LMR was significantly associated with worse overall survival (OS), cancer-specific survival (CSS), and tumor disease or recurrence-free survival (DFS/RFS) in analyses using the studies reporting HRs either by the univariate analyses (HR = 1.32, HR = 1.35, and HR = 1.26 for OS, CSS, and DFS/RFS, resp.) or by multivariate analyses (HR = 1.21, HR = 1.18, and HR = 1.26 for OS, CSS, and DFS/RFS, resp.).Conclusion.Our results support the fact that decreased LMR indicates worse prognosis in multiple digestive system tumors.

VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis

Tumor Biology ◽  
2014 ◽  
Vol 35 (5) ◽  
pp. 4977-4982 ◽  
Author(s):  
Qing Guo ◽  
Sheng-Bin Dai ◽  
Feng Shen ◽  
Di Yu ◽  
Shu-Tong Shen ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Digestive System ◽  
Meta Analysis ◽  
Digestive System Cancer

scholarly journals Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review

2019 ◽  
Vol 2019 ◽  
pp. 1-19
Author(s):  
Linlin Pan ◽  
Tingting Zhang ◽  
Haiyang Sun ◽  
Guirong Liu
Keyword(s):  
Systematic Review ◽  
Digestive System ◽  
Meta Analysis ◽  
Objective Response ◽  
Cochrane Library ◽  
Trial Sequential Analysis ◽  
Karnofsky Performance Scale ◽  
Ginsenoside Rg3 ◽  
Digestive System Cancer

Objective. In China, ginsenoside Rg3 is often used in combination with chemotherapy to treat digestive system cancer. We here performed a meta-analysis and systematic review to provide a much needed high-quality evaluation of the efficacy and safety of ginsenoside Rg3 combined with chemotherapy in these cancers. Materials and Methods. The PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and Weipu (VIP) databases were searched. All randomized controlled trials (RCTs) concerning ginsenoside Rg3 combined with chemotherapy for digestive system cancer were selected. Dichotomous data were expressed as odds ratios (ORs) with 95% confidence intervals (CI). The methodological quality of the included studies was evaluated according to the Cochrane evidence-based medicine system, and the statistical analyses were performed with Review Manager 5.3 and STATA 12.0 software. In addition, the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of the evidence. Trial sequential analysis (TSA) was used to evaluate information size and treatment benefits. Results. A total of 18 trials comprising 1531 patients were included in this study. The results revealed that the trials were of sufficient standard to draw reliable conclusions that ginsenoside Rg3 combined with chemotherapy could improve the objective response rate (ORR; OR 2.17, 95% CI 1.72–2.73), disease control rate (DCR; OR 2.83, 95% CI 2.02–3.96), 1-year survival rate (SR; OR = 2.33, 95% CI = 1.24–4.37), Karnofsky Performance Scale (KPS; OR 2.67, 95% CI 1.76–4.03), gastrointestinal dysfunction (OR 0.44, 95% CI 0.31–0.61), and the decline of leucocyte count (OR 0.28, 95% CI 0.21–0.38). Conclusion. Ginsenoside Rg3 combined with chemotherapy can improve the clinical efficacy and alleviate treatment-induced side effects for digestive system cancer.

scholarly journals Prognostic effect of lncRNA SNHG7 on cancer outcome: a meta and bioinformatic analysis

BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Yunyuan Zhang ◽  
Qingwu Tian ◽  
Shifeng Huang ◽  
Qing Wang ◽  
Hongmei Wu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Prognostic Value ◽  
Digestive System ◽  
Small Sample Size ◽  
Meta Analysis ◽  
Small Sample ◽  
The Cancer Genome Atlas ◽  
Significant Heterogeneity ◽  
Analysis Tool ◽  
Digestive System Cancer

Abstract Background New evidence from clinical and fundamental researches suggests that SNHG7 is involved in the occurrence and development of carcinomas. And the increased levels of SNHG7 are associated with poor prognosis in various kinds of tumors. However, the small sample size was the limitation for the prognostic value of SNHG7 in clinical application. The aim of the present meta-analysis was to conduct a qualitative analysis to explore the prognostic value of SNHG7 in various cancers. Methods Articles related to the SNHG7 as a prognostic biomarker for cancer patients, were comprehensive searched in several electronic databases. The enrolled articles were qualified via the preferred reporting items for systematic reviews and meta-analysis of observational studies in epidemiology checklists. Additionally, an online database based on The Cancer Genome Atlas (TCGA) was further used to validate our results. Results We analyzed 2418 cancer patients that met the specified criteria. The present research indicated that an elevated SNHG7 expression level was significantly associated with unfavorable overall survival (OS) (HR = 2.45, 95% CI: 2.12–2.85, p <0.001). Subgroup analysis showed that high expression levels of SNHG7 were also significantly associated with unfavorable OS in digestive system cancer (HR = 2.31, 95% CI: 1.90–2.80, p <0.001) and non-digestive system cancer (HR = 2.67, 95% CI: 2.12–3.37, p <0.001). Additionally, increased SNHG7 expression was found to be associated with tumor stage and progression (III/IV vs. I/II: HR = 1.76, 95% CI: 1.57–1.98, p <0.001). Furthermore, elevated SNHG7 expression significantly predicted lymph node metastasis (LNM) (HR = 1.98, 95% CI: 1.74–2.26, p <0.001) and distant metastasis (DM) (HR = 2.49, 95% CI: 1.88–3.30, p <0.001) respectively. No significant heterogeneity was observed among these studies. SNHG7 was significantly upregulated in four cancers and the elevated expression of SNHG7 predicted shorter OS in four cancers, worse DFS in five malignancies and worse PFI in five carcinomas based on the validation using the GEPIA on-line analysis tool. Conclusions The present analysis suggests that elevated SNHG7 is significantly associated with unfavorable OS, tumor progression, LNM and DM in various carcinomas, and may be served as a promising biomarker to guide therapy for cancer patients.

Sign in / Sign up

Export Citation Format

Share Document